此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Hutterite Influenza Prevention Study

2011年9月27日 更新者:Mark Loeb、McMaster University

Does Vaccinating Health Hutterite Children Against Influenza Prevent Influenza in Other Hutterite Colony Members: A Randomized Cluster Trial

The goal of this randomized clinical trial is to determine whether immunizing children in Hutterite colonies with inactivated influenza vaccine can prevent influenza and its complications in other colony members. Furthermore, the study will assess the indirect benefit to Hutterites at high risk of complications. The study is a blinded, cluster randomized controlled trial among Hutterite colonies to test the hypothesis that high immunization rates (>70%) of healthy children with inactivated influenza vaccine reduces transmission of influenza to other colony members. Randomization of these homogeneous, moderately sized colonies where there is regular spread facilitated by a communal lifestyle, but limited re-introduction because of relative isolation from outside community, represents a unique opportunity to test the hypothesis of indirect benefit under close to ideal conditions. The primary outcome will be laboratory-confirmed influenza. Secondary outcomes include influenza-like illness, otitis media, physician visits, antimicrobial prescriptions, absenteeism, lower respiratory tract infection, hospitalizations, and death.

研究概览

详细说明

Colonies will be enrolled in September 2008.

Healthy Hutterite Children will be vaccinated in October, in each year of the study (2008, 2009, & 2010)

Influenza Surveillance phase will begin around December-January of each year.

  • All study outcomes will be collected during the Surveillance phase of the study from Dec to June for 3 years.
  • Outcomes will be collected when research nurses visit the colonies. A research nurse will visit enrolled colonies twice a week during the surveillance phase and review study diaries and obtain swabs from participants with symptoms of influenza.

研究类型

介入性

注册 (实际的)

4771

阶段

  • 第四阶段

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

是的

有资格学习的性别

全部

描述

Group A:

Inclusion Criteria:

  • Hutterites other than the healthy children who will be immunized. Although this category as a whole will be used to assess indirect benefit of the vaccine in the main analysis, Hutterites at high risk for influenza complications within this category will be assessed in a separate analysis. These are defined as anyone in one or more of the following groups:
  • individuals aged ≥ 65 years
  • children 23 months of age or less
  • anyone with ≥ 1 of the following conditions severe enough to require regular medical follow-up or hospital care:

    • chronic cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis, and asthma)
    • diabetes mellitus and other metabolic diseases
    • cancer
    • immunodeficiency
    • immunosuppression (due to underlying disease and/or therapy)
    • renal disease
    • anemia
    • hemoglobinopathy
    • any condition that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration.

Exclusion Criteria:

  • There are no exclusion criteria for this category of participants.

Group B:

Inclusion Criteria:

  • Healthy children aged 36 months to 15 years who will be immunized as part of the intervention.

Exclusion Criteria:

  • Anaphylactic reaction to a previous dose of influenza vaccine
  • Anaphylactic reaction to hepatitis A vaccine
  • Anaphylactic reaction to neomycin
  • Known IgE-mediated hypersensitivity to eggs manifested as hives
  • Swelling of the mouth and throat, difficulty in breathing, hypotension, or shock
  • Guillain-Barré syndrome within eight weeks of a previous influenza vaccine.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Influenza
Inactivated Influenza vaccination
Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
其他名称:
  • Vaxigrip by Sanofi Pasteur
安慰剂比较:Control
Hepatitis A vaccine
Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
其他名称:
  • Avaxim Pediatric by Sanofi Pasteur

研究衡量的是什么?

主要结果指标

结果测量
大体时间
laboratory-confirmed influenza infection
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years

次要结果测量

结果测量
大体时间
Influenza like illness
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years
Physician diagnosed otitis media
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years
School or work related absenteeism
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years
Physician visits for respiratory illness
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years
Lower respiratory infection or pneumonia
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years
Hospitalizations for LRTI or pneumonia
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years
All cause hospitalizations
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years
Deaths due to LRTI or pneumonia
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years
All-cause deaths
大体时间:Dec to June each year for 3 years
Dec to June each year for 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mark B Loeb, MD、McMaster University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2008年9月1日

初级完成 (实际的)

2011年5月1日

研究完成 (实际的)

2011年7月1日

研究注册日期

首次提交

2009年1月22日

首先提交符合 QC 标准的

2009年4月6日

首次发布 (估计)

2009年4月7日

研究记录更新

最后更新发布 (估计)

2011年9月28日

上次提交的符合 QC 标准的更新

2011年9月27日

最后验证

2011年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • MCT 88113

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅